Cooley advises Travere Therapeutics, and Latham & Watkins advises the underwriters. Travere Therapeutics, Inc. (Nasdaq: TVTX) has announced the pricing of an underwritten public offering of...
Travere Therapeutics’ $200 Million Public Offering of Common Stock and Pre-Funded Warrants
Mineralys Therapeutics’ $192 Million Initial Public Offering
Latham & Watkins advised Mineralys Therapeutics, and Shearman & Sterling advised the underwriters. Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the pricing of its upsized initial public...
Longboard Pharmaceuticals’ $20 Million Common Stock Offering
Cooley advised Longboard Pharmaceuticals on the offering, and Latham & Watkins advised the underwriters involved. Longboard Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public...
Structure Therapeutics’ $185.3 Million IPO
Cooley LLP represented Structure Therapeutics, while Latham & Watkins LLP represented the underwriters in the offering. Structure Therapeutics, a clinical-stage global biopharmaceutical company, announced its $185.3 million...
Erasca’s $100 Million Common Stock Offering
Latham & Watkins LLP advised Erasca on the offering. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
Prometheus Biosciences’ $500 Million Shares Offering
Wilson Sonsini and Latham & Watkins advised Prometheus Biosciences on the deal, while Davis Polk & Wardwell advised the representatives of the several underwriters. Prometheus Biosciences,...
CG Oncology’s $120 Million Series E Financing Round
Latham & Watkins LLP represented CG Oncology in the transaction. CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic...
Mineralys Therapeutics’ $118 Million Series B Financing
Latham & Watkins represented Mineralys Therapeutics in the transaction. Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the...
HilleVax’s $200 Million Initial Public Offering
Latham & Watkins represented HilleVax, while Davis Polk advised the joint book-running managers in the IPO. HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and...
Travere Therapeutics’ $275 Million Convertible Senior Notes Offering
Latham & Watkins represented the underwriters in the offering. Travere Therapeutics, Inc. executed its offering of US$275 million aggregate principal amount of 2.25% convertible senior notes due...
UCB’s Acquisition of Zogenix
Covington represented UCB, while Latham & Watkins represented Zogenix on the deal. Fried Frank acted as counsel to BofA Securities and SVB Leerink as financial advisors to...
Galderma’s Acquisition of Alastin Skincare
Ropes & Gray advised Galderma on the deal, while Latham & Watkins advised ALASTIN. Galderma, one of the world’s largest independent dermatology companies, executed its acquisition...